CREXONT ER
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Parkinson Disease
Conditions
Parkinson Disease
Trial Timeline
Jul 24, 2025 → May 15, 2027
NCT ID
NCT07138560About CREXONT ER
CREXONT ER is a approved stage product being developed by Amneal Pharmaceuticals for Parkinson Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07138560. Target conditions include Parkinson Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07138560 | Approved | Recruiting |
| NCT06765668 | Approved | Recruiting |
Competing Products
20 competing products in Parkinson Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| LY4006896 + Placebo | Eli Lilly | Phase 1 | 33 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| Equfina 50 mg | Eisai | Pre-clinical | 23 |
| Equfina | Eisai | Pre-clinical | 23 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| Safinamide Mesilate | Eisai | Approved | 85 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
Other Products from Amneal Pharmaceuticals
CREXONT ERApproved
80
Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose PumpPhase 3
72
Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1% + Vehicle Diclofenac Sodium Topical GelPhase 3
72
Phenazopyridine Hydrochloride + PlaceboPhase 3
72
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgPhase 3
72